Summary of measured parameters. by Aaron L. Sayler (19797446)

“…To investigate how the loss of ENBT1 impacts these processes, we generated a <i>slc43a3</i>-null (global; KO) mouse model. …”

Raw data. by Aaron L. Sayler (19797446)

“…To investigate how the loss of ENBT1 impacts these processes, we generated a <i>slc43a3</i>-null (global; KO) mouse model. …”

S1 Raw data - by Dominic Michael Rasp (19959412)

S8 File - by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Study populations of included studies. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Future research directions. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

PRISMA flow diagram. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

S9 File - by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

S7 File - by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Participant characteristics of included studies. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

PTable S4 Expression validation of CYP1B1. by Li-Hong Chen (610826)

“…The transcriptional and translational level of CYP1B1 were obviously increased in the blood tissues. …”

All infection data from the study. by Hala Tamim El Jarkass (16625309)

“…We show that infection causes an increase in the level of <i>C. elegans</i> lipid droplet associated lipase, ATGL-1, and a decrease in host fat levels. …”

mRNA-specific primers of genes. by Li-Hong Chen (610826)

“…The transcriptional and translational level of CYP1B1 were obviously increased in the blood tissues. …”

Basic information of retrieved datasets. by Li-Hong Chen (610826)

“…The transcriptional and translational level of CYP1B1 were obviously increased in the blood tissues. …”

POriginal blots. by Li-Hong Chen (610826)

“…The transcriptional and translational level of CYP1B1 were obviously increased in the blood tissues. …”

PTable S2 Differentially expressed genes. by Li-Hong Chen (610826)

“…The transcriptional and translational level of CYP1B1 were obviously increased in the blood tissues. …”

PTable S5 Markers of each cell cluster. by Li-Hong Chen (610826)

“…The transcriptional and translational level of CYP1B1 were obviously increased in the blood tissues. …”

Blood Pressure and LDL-C During Follow-up. by Karl Ingard (22582091)

“…During a mean follow-up of 3.8 years, 31.7% (n = 64) of the patients in the intervention group and 37.5% (n = 72) in the control group reached the primary endpoint (HR 0.82, 95% CI 0.58–1.14, <i>P</i> = 0.23). The risk of cardiovascular death was significantly decreased (HR 0.64, 95% CI 0.41–0.998, <i>P</i> = 0.049) and the risk of fracture non-significantly increased (HR 1.47, 95% CI 0.95–2.27, <i>P</i> = 0.08) in the intervention group compared to the control group.…”

Baseline Characteristics of Included Patients. by Karl Ingard (22582091)

“…During a mean follow-up of 3.8 years, 31.7% (n = 64) of the patients in the intervention group and 37.5% (n = 72) in the control group reached the primary endpoint (HR 0.82, 95% CI 0.58–1.14, <i>P</i> = 0.23). The risk of cardiovascular death was significantly decreased (HR 0.64, 95% CI 0.41–0.998, <i>P</i> = 0.049) and the risk of fracture non-significantly increased (HR 1.47, 95% CI 0.95–2.27, <i>P</i> = 0.08) in the intervention group compared to the control group.…”

Supplementary file 1_Intercropping of short- and tall-stature maize decreases lodging risk without yield penalty at high planting density.docx by Jianhong Ren (2186293)

“…Moreover, decreased superoxide dismutase (SOD) activity and SPAD, increased malondialdehyde content of ear leaf was observed for intercropped ZD, due to shading stress caused by tall XY. …”